KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$1.35.

  • CRISPR Therapeutics AG's EPS (Basic) fell 22142.86% to -$1.35 in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.5, marking a year-over-year decrease of 4942.53%. This contributed to the annual value of -$6.47 for FY2025, which is 4907.83% down from last year.
  • CRISPR Therapeutics AG's EPS (Basic) amounted to -$1.35 in Q4 2025, which was down 22142.86% from -$1.17 recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's EPS (Basic) registered a high of $10.01 during Q2 2021, and its lowest value of -$2.4 during Q2 2022.
  • Its 5-year average for EPS (Basic) is -$0.81, with a median of -$1.42 in 2023.
  • In the last 5 years, CRISPR Therapeutics AG's EPS (Basic) surged by 87000.0% in 2021 and then crashed by 22142.86% in 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's EPS (Basic) (Quarter) stood at -$1.88 in 2021, then rose by 25.53% to -$1.4 in 2022, then soared by 180.71% to $1.13 in 2023, then crashed by 137.17% to -$0.42 in 2024, then crashed by 221.43% to -$1.35 in 2025.
  • Its EPS (Basic) stands at -$1.35 for Q4 2025, versus -$1.17 for Q3 2025 and -$2.4 for Q2 2025.